Summit Therapeutics Inc.
SMMT
$20.46
$1.668.83%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.44M | 20.39M | 13.97M | 11.73M | 11.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -205.00K | 264.00K | -159.00K | -213.00K | -179.00K |
| Total Operating Expenses | 65.61M | 58.38M | 44.61M | 42.39M | 36.21M |
| Operating Income | -65.61M | -58.38M | -44.61M | -42.39M | -36.21M |
| Income Before Tax | -61.20M | -56.25M | -60.39M | -43.47M | -36.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.20M | -56.25M | -60.39M | -43.47M | -36.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.20M | -56.25M | -60.39M | -43.47M | -36.57M |
| EBIT | -65.61M | -58.38M | -44.61M | -42.39M | -36.21M |
| EBITDA | -65.59M | -58.36M | -44.59M | -42.36M | -36.18M |
| EPS Basic | -0.08 | -0.08 | -0.09 | -0.06 | -0.05 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.04 | -0.04 | -0.03 |
| EPS Diluted | -0.09 | -0.08 | -0.09 | -0.06 | -0.05 |
| Normalized Diluted EPS | -0.05 | -0.05 | -0.04 | -0.04 | -0.03 |
| Average Basic Shares Outstanding | 737.50M | 726.66M | 707.90M | 701.79M | 700.60M |
| Average Diluted Shares Outstanding | 737.50M | 726.66M | 707.90M | 701.79M | 700.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
